Silverarc Capital Management, LLC Immatics N.V. Transaction History

Silverarc Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$5.92 - $12.72 $1.49 Million - $3.2 Million	-251,717 Reduced 89.12%	30,715 $354,000
Q1 2023 May 15, 2023	SELL	$6.74 - $9.44 $1.06 Million - $1.49 Million	-157,356 Reduced 35.78%	282,432 $1.95 Million
Q4 2022 Feb 14, 2023	BUY	$8.05 - $11.58 $2.22 Million - $3.19 Million	275,850 Added 168.26%	439,788 $3.83 Million
Q3 2022 Oct 28, 2022	SELL	$3.31 - $13.06 $632,756 - $2.5 Million	-191,165 Reduced 53.83%	163,938 $1.64 Million
Q2 2022 Jul 25, 2022	SELL	$6.0 - $9.37 $541,386 - $845,464	-90,231 Reduced 20.26%	355,103 $3.09 Million
Q1 2022 May 13, 2022	BUY	$6.64 - $12.85 $359,748 - $696,200	54,179 Added 13.85%	445,334 $3.56 Million
Q4 2021 Feb 14, 2022	SELL	$10.81 - $14.38 $504,945 - $671,704	-46,711 Reduced 10.67%	391,155 $5.26 Million
Q3 2021 Nov 15, 2021	BUY	$11.58 - $15.46 $1.72 Million - $2.3 Million	148,458 Added 51.3%	437,866 $5.69 Million
Q2 2021 Aug 16, 2021	BUY	$10.43 - $12.81 $2.58 Million - $3.17 Million	247,611 Added 592.41%	289,408 $3.36 Million
Q1 2021 May 18, 2021	BUY	$10.24 - $14.6 $428,001 - $610,236	41,797 New	41,797 $469,000

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $623M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.